Alembic Pharmaceuticals Limited — Updates, 20-12-2024: Press Release

Alembic Pharmaceuticals has received Final Approval from the USFDA for its Divalproex Sodium Delayed-Release Capsules USP, 125 mg. This product is therapeutically equivalent to AbbVie’s Depakote Sprinkle Capsules, 125 mg, and is indicated for various seizure disorders. The estimated market size for Divalproex Sodium in the U.S. is around USD 61.1 million for the twelve months ending September 2024. With this approval, Alembic has achieved a total of 220 ANDA approvals from the USFDA, comprising 193 final and 27 tentative approvals. This development highlights Alembic's strong position in the generic pharmaceuticals market and its ongoing commitment to expanding its product portfolio. Investors should view this approval as a positive indication of growth potential in the anti-epileptic segment.